

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-439

10/579,230

APPLICANT

VELDMAN et al.

(Use several sheets if necessary)

FILING DATE

GROUP

May 12, 2006

unknown

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----------------|--------------|---------|-----------|----------|-------------------------------|
| | 1 | 4,416,872 | 11/1983 | Alving | | |
| | 2 | 5,013,556 | 05/1991 | Woodle | | |
| | 3 | 5,213,804 | 05/1993 | Martin | | |
| | 4 | 5,395,619 | 03/1995 | Zalipsiky | | |
| | 5 | 5,527,528 | 06/1996 | Allen | | |
| | 6 | 5,800,833 | 09/1998 | Hope | | |
| | 7 | 2002/0119990 | 08/2002 | Madden | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
|--|----------|--------------|---------|--------|----------|-----------------------|
| | 8 | WO 88/01171 | 02/1988 | WIPO | | |
| | 9 | WO 99/41266 | 08/1999 | WIPO | | |
| | 10 | WO 02/02077 | 01/2002 | WIPO | | |
| | 11 | EP 0 896 816 | 02/1999 | Europe | | |
| | 12 | JP 8-034746 | 02/1996 | Japan | | X |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

| | |
|----|---|
| 13 | Abraham SA, et al, 2002, "Formation of transition metal-doxorubicin complexes inside liposomes," <u>Biochim. Biophys. Acta.</u> , Vol. 1565(1), pp. 41-54. |
| 14 | Bai J, et al, 1997, "Measurement of spontaneous transfer and transbilayer movement of BODIPY-labeled lipids in lipid vesicles," <u>Biochemistry</u> , Vol. 36, pp. 8840-8848. |
| 15 | Bligh EJ, et al, 1959, "A rapid method of total lipid extraction and purification," <u>Can. J. Biochem. Physiol.</u> , Vol. 37, pp. 911-917. |
| 16 | Carmichael J, et al, 1987, "Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing," <u>Cancer Res.</u> , Vol. 47, pp. 936-942. |
| 17 | Cheung BC, et al, 1998, "Loading of doxorubicin into liposomes by forming Mn ²⁺ -drug complexes," <u>Biochim. Biophys. Acta.</u> , Vol. 1414(1-2), pp. 205-216. |
| 18 | Druckmann S, et al, 1989, "Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies," <u>Biochim. Biophys. Acta.</u> , Vol. 980, pp. 381-384. |
| 19 | Everts M, et al, 2003, "In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium," <u>Pharm. Res.</u> , Vol. 20, pp. 64-72. |
| 20 | Gabizon A, 2001, "Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy," <u>Cancer Inv.</u> , Vol. 19, pp. 424-436. |

| | | | |
|-----------|-----------------|-----------------|------------|
| *Examiner | /Michael Henry/ | Date Considered | 01/02/2010 |
|-----------|-----------------|-----------------|------------|

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-439

10/579,230

APPLICANT

VELDMAN et al.

(Use several sheets if necessary)

FILING DATE

GROUP

May 12, 2006

unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

| | |
|----|--|
| 21 | Gabizon A, et al, 1996, "Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines," <u>J. Drug Target</u> , Vol. 3, pp. 391-398. |
| 22 | Ghidoni R, et al, 1999, "Use of sphingolipid analogs: benefits and risks," <u>Biochim. Biophys. Acta</u> , Vol. 1439, pp. 17-39. |
| 23 | Haran G, et al Y, 1993, "Transmembrane ammonium sulphate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases," <u>Biochim. Biophys. Acta</u> , Vol. 1151, pp. 201-215. |
| 24 | Harasym TO, et al, 1997, "Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/ cholesterol liposomes," <u>Cancer Chemother. Pharmacol.</u> , Vol. 40, pp. 309-317. |
| 25 | Heijn M, et al, 1999, "Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor," <u>Cancer Res.</u> , Vol. 59, pp. 4458-4463. |
| 26 | Horowitz AT, et al, 1992, "In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release," <u>Biochim. Biophys. Acta</u> , Vol. 1109, pp. 203-209. |
| 27 | Jeckel D, et al, 1993, "Truncated ceramide analogs as probes for sphingolipid biosynthesis and transport," <u>Adv. Lipid Res.</u> , Vol. 26, pp. 143-160. |
| 28 | Koning GA, et al, 1999, "Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells," <u>Br. J. Cancer</u> , Vol. 80, pp. 1718-1725. |
| 29 | Koning GA, et al, 2003, "Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer Cells. An in vitro comparison," <u>Pharm. Res.</u> , Vol. 20, pp. 1249-1257. |
| 30 | Koning, G.A., et al, 2003, "Short-chain liposomal sphingolipids potentiate in vitro doxorubicin cytotoxicity by enhancing its cellular influx," Conference Abstract for Liposome Advances: Progress in Drug and Vaccine Delivery, 15-19 December 2003, London, UK. |
| 31 | Lasic DD, et al, 1995, "Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery," <u>Biochim. Biophys. Acta.</u> , Vol. 1239(2), pp. 145-156. |
| 32 | Lothstein L, et al, 2001, "Anthracyclin drug targeting: cytoplasmic versus nuclear - a fork in the road," <u>Drug Res. Updates</u> , Vol. 4, pp. 169-177. |
| 33 | Mabrey, S., et al, 1978, "High-sensitivity scanning calorimetric study of mixtures of cholesterol with dimyristoyl- and dipalmitoylphosphatidylcholines", <u>Biochem.</u> , Vol. 17, pp. 2464-2468. |
| 34 | Martin, F.J., 1990, "Pharmaceutical Manufacturing of Liposomes", <u>Specialized Drug Delivery Systems - Manufacturing and Production Technology</u> , pp. 267-316. |

*Examiner

/Michael Henry/

Date Considered

01/02/2010

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.C.H./

| | | |
|--|------------------|------------|
| INFORMATION DISCLOSURE CITATION | ATTY. DOCKET NO. | SERIAL NO. |
| | 620-439 | 10/579,230 |
| (Use several sheets if necessary) | APPLICANT | |
| | VELDMAN et al. | |
| | FILING DATE | GROUP |
| | May 12, 2006 | unknown |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

| | |
|----|--|
| 35 | Mayer, L.D., et al, 1986, "Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient", <u>Biochim. Biophys. Acta</u> , Vol. 857, pp. 123-126. |
| 36 | Mayer, L.D., et al., 1989, "Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in Mice", <u>Cancer Res.</u> , Vol. 49, pp. 5922-5930. |
| 37 | Olson, F., et al, 1979, "Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes", <u>Biochim. Biophys. Acta</u> , Vol. 557, pp. 9-23. |
| 38 | Pan, XQ, et al, 2003, "Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model," <u>Pharm. Res.</u> , Vol. 20, pp. 417-422. |
| 39 | Park, JW, et al, 2002, "Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery," <u>Clin. Cancer Res.</u> , Vol. 8, pp. 1172-1181. |
| 40 | Robert J, et al, 1993, "Pharmacokinetics and metabolism of anthracyclines," in <u>Cancer Surveys</u> , Vol. 17, pp. 219-252. |
| 41 | Rouser G, et al, 1970, "Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots," <u>Lipids</u> , Vol. 5, pp. 494-496. |
| 42 | Sillence, D.J., et al., 2000, "Assay for the transbilayer distribution of glycolipids: selective oxidation of glucosylceramide to glucuronylceramide by TEMPO nitroxyl radicals", <u>Journal of Lipid Research</u> , Vol. 41, pp. 1252-1260. |
| 43 | Smith PK, et al, 1985, "Measurement of protein using bicinchoninic acid," <u>Anal. Chem.</u> , Vol. 150, pp. 76-85. |
| 44 | Speth PA, et al, 1988, "In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells," <u>Eur. J. Cancer Clin. Oncol.</u> , Vol. 24, pp. 667-674. |
| 45 | Storm G, et al, 1985, "The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation", <u>Biochim. Biophys. Acta</u> , Vol. 818, pp. 343-351. |
| 46 | Szoka, F., Jr., et al, 1980, "Comparative properties and methods of preparation of lipid vesicles (liposomes)", <u>Ann. Rev. Biophys. Biogen.</u> , Vol. 9, p. 457. |
| 47 | Tardi PG, et al, 1996, "Liposomal doxorubicin," <u>J. Drug Target</u> , Vol. 4, pp. 129-140. |
| 48 | Tsong, T.Y., 1975, "Effect of phase transition on the kinetics of dye transport in phospholipid bilayer structures", <u>Biochem.</u> , Vol. 14, pp. 5409-5414; pp. 5415-5417. |
| 49 | Tubaro, E., et al, 1995, "Effect of a new de-N-acetyl-lysoglycosphingolipid on some tumour models," <u>European Journal of Pharmacology</u> , Vol. 294, pp. 555-563. |
| 50 | Uster PS, et al, 1996, "Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time," <u>FEBS Lett.</u> , Vol. 386, pp. 243-246. |

| | | | |
|-----------|-----------------|-----------------|------------|
| *Examiner | /Michael Henry/ | Date Considered | 01/02/2010 |
|-----------|-----------------|-----------------|------------|

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet 4 of 4

| | | |
|--|------------------|------------|
| INFORMATION DISCLOSURE CITATION | ATTY. DOCKET NO. | SERIAL NO. |
| | 620-439 | 10/579,230 |
| (Use several sheets if necessary) | APPLICANT | |
| | VELDMAN et al. | |
| | FILING DATE | GROUP |
| | May 12, 2006 | unknown |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

| | |
|----|--|
| 51 | Vaage J, et al, 1992, "Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes," <u>Int. J. Cancer</u> , Vol. 51, pp. 942-948. |
| 52 | Veldman, R.J., et al, 2004, "N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx," <u>British Journal of Cancer</u> , Vol. 90, pp. 917-925. |
| 53 | Veldman, R.J., et al., 1999, "Inhibition of P-glycoprotein activity and chemosensitization of multidrug-resistant ovarian carcinoma 2780AD cells by hexanoylglucosylceramide", <u>Biochemical & Biophysical Research Communications</u> , Vol. 266, pp. 492-496. |
| 54 | Verheij, M., et al, 2003, "N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx," Conference Abstract #C228 for AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 17-21 November 2003, Boston, MA, USA. |
| 55 | Washington N, et al, 2001, "Cell membranes, epithelial barriers and drug absorption," in <u>Physiological Pharmaceutics: Barriers to Drug Absorption</u> , pp. 1-18, (publishers: Taylor and Francis: London). |
| 56 | Weiss RB, 1992, "The anthracyclines: will we ever find a better doxorubicin?", <u>Sem. Oncol.</u> , Vol. 19, pp. 670-686. |
| 57 | Yuan F, et al, 1994, "Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft," <u>Cancer Res.</u> , Vol. 54, pp. 3352-3356. |
| 58 | Zagotto G, et al, 2001, "Anthracyclins: recent developments in their separation and quantitation," <u>J. Chromat. B</u> , Vol. 764, pp. 161-171. |
| 59 | International Preliminary Report on Patentability (IPRP) of PCT/GB2004/003886. |
| 60 | International Search Report (ISR) of PCT/GB2004/003886. |
| 61 | Search Report of GB 0326642.6. |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| | | | |
|-----------|-----------------|-----------------|------------|
| *Examiner | /Michael Henry/ | Date Considered | 01/02/2010 |
|-----------|-----------------|-----------------|------------|

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.C.H./